CN113573702A - 用于癌症治疗的亚达司他的组合 - Google Patents

用于癌症治疗的亚达司他的组合 Download PDF

Info

Publication number
CN113573702A
CN113573702A CN202080018266.2A CN202080018266A CN113573702A CN 113573702 A CN113573702 A CN 113573702A CN 202080018266 A CN202080018266 A CN 202080018266A CN 113573702 A CN113573702 A CN 113573702A
Authority
CN
China
Prior art keywords
combination
inhibitor
cancer
pharmaceutically acceptable
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080018266.2A
Other languages
English (en)
Chinese (zh)
Inventor
F·西赛里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oryzon Genomics SA
Original Assignee
Oryzon Genomics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oryzon Genomics SA filed Critical Oryzon Genomics SA
Priority to CN202511368496.2A priority Critical patent/CN121422229A/zh
Publication of CN113573702A publication Critical patent/CN113573702A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080018266.2A 2019-03-25 2020-03-25 用于癌症治疗的亚达司他的组合 Pending CN113573702A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202511368496.2A CN121422229A (zh) 2019-03-25 2020-03-25 用于癌症治疗的亚达司他的组合

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382206 2019-03-25
EP19382206.1 2019-03-25
PCT/EP2020/058362 WO2020193631A1 (en) 2019-03-25 2020-03-25 Combinations of iadademstat for cancer therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202511368496.2A Division CN121422229A (zh) 2019-03-25 2020-03-25 用于癌症治疗的亚达司他的组合

Publications (1)

Publication Number Publication Date
CN113573702A true CN113573702A (zh) 2021-10-29

Family

ID=66175363

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080018266.2A Pending CN113573702A (zh) 2019-03-25 2020-03-25 用于癌症治疗的亚达司他的组合
CN202511368496.2A Pending CN121422229A (zh) 2019-03-25 2020-03-25 用于癌症治疗的亚达司他的组合

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202511368496.2A Pending CN121422229A (zh) 2019-03-25 2020-03-25 用于癌症治疗的亚达司他的组合

Country Status (13)

Country Link
US (1) US20220175698A1 (cg-RX-API-DMAC7.html)
EP (1) EP3946295B1 (cg-RX-API-DMAC7.html)
JP (2) JP7824627B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210142614A (cg-RX-API-DMAC7.html)
CN (2) CN113573702A (cg-RX-API-DMAC7.html)
AU (1) AU2020249493B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021016171A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132473A1 (cg-RX-API-DMAC7.html)
IL (1) IL286353A (cg-RX-API-DMAC7.html)
MX (1) MX2021011610A (cg-RX-API-DMAC7.html)
PH (1) PH12021552326A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109025XA (cg-RX-API-DMAC7.html)
WO (1) WO2020193631A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913290QA (en) 2016-03-15 2020-03-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for the treatment of hematological malignancies
SI3941466T1 (sl) 2019-03-20 2026-04-30 Oryzon Genomics, S.A. Vafidemstat za zdravljenje neagresivnih simptomov mejne osebnostne motnje

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018083138A1 (en) * 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9469597B2 (en) 2011-10-20 2016-10-18 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
EP3090998A1 (en) 2015-05-06 2016-11-09 F. Hoffmann-La Roche AG Solid forms
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
US11685782B2 (en) * 2017-10-23 2023-06-27 Children's Medical Center Corporation Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018083138A1 (en) * 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JUNZO HAMANISHI等: "PD-1/PD-L1 blockade in cancer treatment: perspectives and issues", 《INT J CLIN ONCOL》, vol. 21, 22 February 2016 (2016-02-22), pages 1 *
WANQIANG SHENG等: "LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade", 《CELL》, vol. 174, 26 July 2018 (2018-07-26), pages 7 *

Also Published As

Publication number Publication date
JP7824627B2 (ja) 2026-03-05
SG11202109025XA (en) 2021-09-29
JP2026077769A (ja) 2026-05-13
KR20210142614A (ko) 2021-11-25
AU2020249493A1 (en) 2021-09-16
PH12021552326A1 (en) 2022-06-27
JP2022526525A (ja) 2022-05-25
EP3946295A1 (en) 2022-02-09
BR112021016171A2 (pt) 2021-10-05
CA3132473A1 (en) 2020-10-01
CN121422229A (zh) 2026-01-30
US20220175698A1 (en) 2022-06-09
WO2020193631A1 (en) 2020-10-01
EP3946295B1 (en) 2026-08-05
AU2020249493B2 (en) 2025-08-28
IL286353A (en) 2021-10-31
MX2021011610A (es) 2021-10-13

Similar Documents

Publication Publication Date Title
JP2019517549A5 (cg-RX-API-DMAC7.html)
JP2022531939A (ja) がんを処置する方法
IL263110B (en) Combined treatment of notch and pd-1 or pd-l1 inhibitors
US12427142B2 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl[oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid
JP2026077769A (ja) 癌療法のためのイアダデムスタット(iadademstat)の組み合わせ物
CN104684579A (zh) 单特异性的和双特异性的抗-IGF-1R 和抗-ErbB3 抗体的剂量和施用
CN120826242A (zh) 抗cd20抗体药物偶联物在制备治疗套细胞淋巴瘤的药物中的用途
TW200306185A (en) Combinations comprising EPOTHILONES and anti-metabolites
JP2022547061A5 (cg-RX-API-DMAC7.html)
RU2833564C2 (ru) Комбинации иададемстата для лечения рака
TW202308641A (zh) 用於治療癌症之方法及包含cdk抑制劑之給藥方案
TWI671072B (zh) 曲氟尿苷(trifluridine)/替匹拉希(tipiracil)鹽酸鹽、抗腫瘤鉑錯合物及免疫檢查點調節子之間的新穎組合
TWI882612B (zh) 藥物組合及其應用
US20250302781A1 (en) Method for pretreating relapsing cancer
KR102356393B1 (ko) 두경부암의 치료 또는 예방에 사용하기 위한 pi3 키나제 억제제와 파클리탁셀의 조합물
TW201944997A (zh) 西達本胺與依西美坦在製備用於治療乳腺癌的聯合用藥物中的用途及聯合用藥物
US20030139430A1 (en) Use of organic compounds
JP2025516649A5 (cg-RX-API-DMAC7.html)
TH2201001953A (th) การรักษาของโรคตับอักเสบจากแอลกอฮอล์
HK40015395A (en) Combination between trifluridine/tipiracil hydrochloride, an anti-tumor platinum complex, and an immune checkpoint modulator

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination